Content about Menstrual cycle

SAN DIEGO — Women who take low-dose oral contraceptives may be at increased risk of chronic pelvic-pain symptoms and pain during sexual climax, according to a new study.

The study, scheduled for presentation to reporters at the American Urological Association's annual scientific meeting in San Diego on Tuesday, was conducted by researchers at New York University and the Waitemata District Health Board in Auckland, New Zealand, compared CPPS in young women who used oral contraceptives with the condition in those who didn't.

JERUSALEM — The Food and Drug Administration has approved a new contraceptive therapy made by Teva Pharmaceutical Industries, Teva said Monday.

The drug maker announced the approval of Quartette (levonorgestrel, ethinyl estradiol and ethinyl estradiol) tablets. Teva said the drug represented the "next generation" of extended-regimen oral contraceptives and was designed to minimize breakthrough bleeding between scheduled periods.

NEW YORK — In View, the Discovery Channel program of which Larry King is host, will include a feature about DivaCup, a reusable menstrual cup.

The show will air on March 7 at 7 a.m., examining the product and its role in feminine hygiene and featuring the mother and daughter who created it, Francine and Carinne Chambers. The product is made from healthcare-grade silicone and is designed to reduce the amount of disposable feminine hygiene waste created each year.

NEW YORK — The Electronic Retailing Self-Regulation Program on Tuesday recommended that Casper Labs modify or discontinue certain claims for Calmestra, a dietary supplement marketed as providing relief for symptoms of menopause, including claims that the product has been “clinically proven” to address symptoms of menopause.

NEW YORK — The National Advertising Division on Thursday recommended that Church & Dwight discontinue its claim that the company’s First Response digital ovulation test is the “first and only test to predict ovulation based on your unique LH hormone level.”

The claim, which appeared on product packaging and on the company’s website, was challenged by SPD Swiss Precision Diagnostics, the maker of the Clearblue DOT, a competing digital ovulation test product.

FLORHAM PARK, N.J. — The Food and Drug Administration has accepted a regulatory approval application for a drug made by Shionogi for treating vulvar and vaginal atrophy due to menopause.

Shionogi, the U.S. division of Japanese drug maker Shionogi & Co., said Wednesday that the FDA had accepted for review its application for ospemifene, which the company touts as potentially the first oral alternative to vaginal estrogen treatments.

WEST ORANGE, N.J. — Everett Labs on Monday announced the launch of Pregnitude, a dietary supplement that helps support ovulation function and menstrual cycle regularity for women who are interested in conceiving.

WAYNE, N.J. — The Food and Drug Administration has approved a drug that the manufacturer called the first oral contraceptive that also treats heavy menstrual bleeding.

Bayer HealthCare Pharmaceuticals announced Wednesday the approval of Natazia (estradiol valerate and estradiol valerate and dienogest) tablets for heavy menstrual bleeding not caused by any conditions of the uterus. The drug was originally approved as an oral contraceptive in May 2010.

PARSIPPANY, N.J. — Watson has launched an authorized generic drug for treating postmenopausal women, the company said Friday.

Watson announced the launch of progesterone capsules in the 100-mg and 200-mg strengths, an authorized generic version of Abbott Labs' Prometrium, under an agreement with Abbott. Abbott will manufacture the drug and supply it to Watson, which will market and distribute it and share profits. Other terms were not disclosed, the companies said.

CROMWELL, Conn. — Amerifit Brands on Wednesday launched its Azo PMS product, which has been formulated to help reduce moodiness, irritability and bloating with a variety of ingredients, including high-potency B vitamins, calcium, magnesium, folic acid and two natural herbal blends, the company stated.

PRINCETON, N.J. — Church & Dwight on Tuesday announced the launch of its First Response digital ovulation test, a new at-home ovulation test that can detect a woman's personal luteinizing hormone, or LH, surge — the hormonal indication of ovulation — based on her own individual hormone levels.

CINCINNATI Procter & Gamble's feminine protection brand, Always, has launched its Always Me mobile application that enables women to track their period and ovulation.

Not just a standard period and ovulation tracker, the Always Me application is a personalized, on-the-go application that helps women manage their cycles and offers timely support and advice.